← Back to Search

Psychedelic

Psilocybin therapy for Bipolar Disorder (BAP Trial)

Phase 2
Waitlist Available
Led By Joshua D Woolley, MD,PhD
Research Sponsored by University of California, San Francisco
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to 3 months following last drug dose
Awards & highlights

Summary

This trial is testing the safety and feasibility of using psilocybin, a substance from 'magic mushrooms,' to help people with Bipolar II Disorder who are currently depressed. Researchers want to see if this treatment can safely improve mood and quality of life for these patients. Psilocybin has shown promise as a treatment for depression and has been designated as a breakthrough therapy by the FDA.

Eligible Conditions
  • Bipolar Disorder

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to 3 months following last drug dose
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to 3 months following last drug dose for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Clinician-reported effects of psilocybin therapy on depressive symptoms in people with Bipolar II
Clinician-reported effects of psilocybin therapy on mania symptoms in people with Bipolar II
Clinician-reported effects of psilocybin therapy on suicidality symptoms in people with Bipolar II
+5 more
Secondary study objectives
Effects of psilocybin therapy on adult attachment in people with Bipolar II (exploratory)
Effects of psilocybin therapy on anxiety symptoms in people with Bipolar II (exploratory)
Effects of psilocybin therapy on borderline personality disorder symptoms in people with Bipolar II (exploratory)
+5 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Psilocybin therapyExperimental Treatment1 Intervention
Participants will receive one or two doses of psilocybin in a monitored setting approximately three weeks apart, with preparation sessions before and integration sessions after.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Psilocybin therapy
2021
Completed Phase 2
~20

Find a Location

Who is running the clinical trial?

University of California, San FranciscoLead Sponsor
2,551 Previous Clinical Trials
15,257,872 Total Patients Enrolled
1 Trials studying Bipolar Disorder
59 Patients Enrolled for Bipolar Disorder
Joshua D Woolley, MD,PhDPrincipal InvestigatorUniversity of California, San Francisco
David Guard, PhDStudy DirectorSan Francisco State University
~4 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top